share_log

賽生藥業:根據《收購守則》規則22作出的交易披露

SCICLONE PHARMA: Disclosure of Dealings under Rule 22 of the Takeovers Code

Hong Kong Stock Exchange ·  Apr 19 04:45
Summary by Moomoo AI
赛生药业(SCICLONE PHARMA)於2024年4月19日宣布,公司執行人員Peter Shao Chihwen根據香港《公司收購及合併守則》規則22,於2024年4月18日接受了195,000份股票期權。該期權的行使期限自2024年4月18日起至2030年4月18日,行使價為每股7.8920美元,而期權金額為0.0000美元。此次交易後,Peter Shao Chihwen持有的賽生药业股份總數達到2,740,000股。該交易是根據公司的購股權激勵計劃進行,並且是為本身帳戶進行的。
赛生药业(SCICLONE PHARMA)於2024年4月19日宣布,公司執行人員Peter Shao Chihwen根據香港《公司收購及合併守則》規則22,於2024年4月18日接受了195,000份股票期權。該期權的行使期限自2024年4月18日起至2030年4月18日,行使價為每股7.8920美元,而期權金額為0.0000美元。此次交易後,Peter Shao Chihwen持有的賽生药业股份總數達到2,740,000股。該交易是根據公司的購股權激勵計劃進行,並且是為本身帳戶進行的。
SCICLONE PHARMA (SCICLONE PHARMA) announced on 19 April 2024 that its Chief Executive Officer, Peter Shao Chihwen, received 195,000 share options on 18 April 2024 under Rule 22 of the Hong Kong Code of Companies. The option has an exercise period from April 18, 2024 to April 18, 2030, at an exercise price of $7.8920 per share and an option amount of $0.0000. Following this transaction, Peter Shao Chihwen's total shares in Sai Pharma reached 2,740,000 shares. The transaction was conducted under the Company's Share Incentive Scheme and was conducted for its own account.
SCICLONE PHARMA (SCICLONE PHARMA) announced on 19 April 2024 that its Chief Executive Officer, Peter Shao Chihwen, received 195,000 share options on 18 April 2024 under Rule 22 of the Hong Kong Code of Companies. The option has an exercise period from April 18, 2024 to April 18, 2030, at an exercise price of $7.8920 per share and an option amount of $0.0000. Following this transaction, Peter Shao Chihwen's total shares in Sai Pharma reached 2,740,000 shares. The transaction was conducted under the Company's Share Incentive Scheme and was conducted for its own account.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more